WO2008047023A3 - Immunisation method against the 4 dengue serotypes - Google Patents

Immunisation method against the 4 dengue serotypes Download PDF

Info

Publication number
WO2008047023A3
WO2008047023A3 PCT/FR2007/052054 FR2007052054W WO2008047023A3 WO 2008047023 A3 WO2008047023 A3 WO 2008047023A3 FR 2007052054 W FR2007052054 W FR 2007052054W WO 2008047023 A3 WO2008047023 A3 WO 2008047023A3
Authority
WO
WIPO (PCT)
Prior art keywords
dengue
serotype
dose
series
dengue serotypes
Prior art date
Application number
PCT/FR2007/052054
Other languages
French (fr)
Other versions
WO2008047023A2 (en
Inventor
Bruno Guy
Remi Forrat
Jean Lang
Veronique Barban
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Priority to CA002663885A priority Critical patent/CA2663885A1/en
Priority to AU2007311792A priority patent/AU2007311792B2/en
Priority to CN2007800444299A priority patent/CN101553251B/en
Priority to EP07858487.7A priority patent/EP2077857B1/en
Priority to MX2009003417A priority patent/MX2009003417A/en
Priority to JP2009530916A priority patent/JP5269796B2/en
Priority to BRPI0719849-3A2A priority patent/BRPI0719849A2/en
Publication of WO2008047023A2 publication Critical patent/WO2008047023A2/en
Publication of WO2008047023A3 publication Critical patent/WO2008047023A3/en
Priority to IL197768A priority patent/IL197768A0/en
Priority to IL224572A priority patent/IL224572A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention relates to a method for inducing a protection against the 4 dengue serotypes in a patient, that comprises: (a) a first series of administrations (i) of a dose of a dengue vaccinal virus of a first serotype and a dose of a dengue vaccinal virus of a second serotype, and (ii) of a dose of a dengue vaccinal virus of a third serotype and a dose of a dengue vaccinal virus of a fourth serotype, and (b) a second series of administrations of the (i) and (ii) doses, wherein the (i) and (ii) doses are administered simultaneously at separate anatomical sites and wherein the second series is administered at least 30 days and at most 12 months after the first series.
PCT/FR2007/052054 2006-10-04 2007-10-02 Immunisation method against the 4 dengue serotypes WO2008047023A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA002663885A CA2663885A1 (en) 2006-10-04 2007-10-02 Immunisation method against the 4 dengue serotypes
AU2007311792A AU2007311792B2 (en) 2006-10-04 2007-10-02 Immunisation method against the 4 dengue serotypes
CN2007800444299A CN101553251B (en) 2006-10-04 2007-10-02 Immunisation method against the 4 dengue serotypes
EP07858487.7A EP2077857B1 (en) 2006-10-04 2007-10-02 Immunisation method against the 4 dengue serotypes
MX2009003417A MX2009003417A (en) 2006-10-04 2007-10-02 Immunisation method against the 4 dengue serotypes.
JP2009530916A JP5269796B2 (en) 2006-10-04 2007-10-02 Methods for immunization against four dengue serotypes
BRPI0719849-3A2A BRPI0719849A2 (en) 2006-10-04 2007-10-02 IMMUNIZATION METHOD AGAINST THE DENGUE'S FOUR SEROTIES
IL197768A IL197768A0 (en) 2006-10-04 2009-03-23 Immunisation method against the 4 dengue serotypes
IL224572A IL224572A (en) 2006-10-04 2013-02-04 Kit for inducing neutralizing antibodies against the four dengue virus serotypes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0608660A FR2906724B1 (en) 2006-10-04 2006-10-04 METHOD OF IMMUNIZATION AGAINST THE 4 SEROTYPES OF DENGUE.
FR0608660 2006-10-04

Publications (2)

Publication Number Publication Date
WO2008047023A2 WO2008047023A2 (en) 2008-04-24
WO2008047023A3 true WO2008047023A3 (en) 2008-10-23

Family

ID=38222583

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/052054 WO2008047023A2 (en) 2006-10-04 2007-10-02 Immunisation method against the 4 dengue serotypes

Country Status (15)

Country Link
US (2) US7718358B2 (en)
EP (3) EP2077857B1 (en)
JP (1) JP5269796B2 (en)
KR (1) KR20090064593A (en)
CN (2) CN101553251B (en)
AR (1) AR063057A1 (en)
AU (1) AU2007311792B2 (en)
BR (1) BRPI0719849A2 (en)
CA (1) CA2663885A1 (en)
FR (1) FR2906724B1 (en)
IL (2) IL197768A0 (en)
MX (1) MX2009003417A (en)
TW (2) TW201336508A (en)
WO (1) WO2008047023A2 (en)
ZA (1) ZA200901816B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0614265A2 (en) * 2005-08-10 2011-03-22 Acambis Inc use of a yellow fever virus vaccine and a chimeric flavivirus vaccine and kit containing such vaccines
FR2903605A1 (en) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa IMMUNIZATION METHOD AGAINST THE FOUR SEROTYPES OF DENGUE
FR2909286B1 (en) * 2006-12-01 2012-06-08 Sanofi Pasteur IMMUNIZATION METHOD AGAINST THE 4 SEROTYPES OF DENGUE
AU2009221180B2 (en) 2008-03-05 2014-02-13 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
EP2143440A1 (en) * 2008-07-09 2010-01-13 Sanofi Pasteur Stabilising agent and vaccine composition comprising one or several attenuated living flavivirus
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
EP2438198A4 (en) * 2009-06-01 2014-05-14 Inviragen Inc Compositions and methods for administration of vaccines against dengue virus
JP6057460B2 (en) 2009-08-31 2017-01-11 ジェン−プローブ・インコーポレーテッド Dengue virus assay
EP2353609A1 (en) * 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
EP2550298B1 (en) 2010-03-23 2015-07-15 The Regents of The University of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
AU2012275319A1 (en) * 2011-06-29 2013-11-14 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of Dengue virus infection
JP2015520196A (en) * 2012-06-10 2015-07-16 タケダ ワクチン，インコーポレイテッドＴａｋｅｄａ Ｖａｃｃｉｎｅｓ，Ｉｎｃ． Compositions and methods for vaccine administration against dengue virus
US8895028B2 (en) * 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
KR20150036592A (en) 2012-07-24 2015-04-07 사노피 파스퇴르 Vaccine compositions
WO2014016362A1 (en) 2012-07-24 2014-01-30 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
BR112015012515B1 (en) 2012-11-30 2023-04-11 Sanofi Pasteur USE OF ANTIGENS, NUCLEIC ACID CONSTRUCTS OR VIRAL VECTORS CAPABLE OF EXPRESSING A VIRUS-LIKE PARTICLE (VLP) OF DENGUE AND A VACCINE AGAINST MEASLES, A VACCINE AGAINST MUMPS AND A VACCINE AGAINST RUBELLA
CA2933472A1 (en) * 2012-12-14 2014-06-19 Takeda Vaccines, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
EP3010536A4 (en) 2013-06-21 2016-11-30 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
TW201620546A (en) 2014-09-02 2016-06-16 賽諾菲巴斯德公司 Vaccine compositions
EP3236997A4 (en) 2014-12-22 2018-05-30 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
EP3382012A4 (en) * 2015-11-27 2019-07-03 KM Biologics Co., Ltd. Live virus having a bank of dengue virus attenuated strains, and a dengue vaccine containing same as antigens
US11690903B2 (en) 2017-10-05 2023-07-04 Sanofi Pasteur Compositions for booster vaccination against dengue
BR112021003962A2 (en) 2018-09-05 2021-05-25 Takeda Vaccines, Inc. unit dose of dengue vaccine and its administration
JP2022544613A (en) 2019-08-16 2022-10-19 タケダ ワクチン，インコーポレイテッド Method for preventing dengue fever and hepatitis A
JP2023516009A (en) 2020-02-27 2023-04-17 タケダ ワクチン，インコーポレイテッド Methods for removing host cell DNA from virus preparations
WO2023147342A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2023158989A1 (en) 2022-02-15 2023-08-24 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
WO2023215383A1 (en) 2022-05-04 2023-11-09 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057910A1 (en) * 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-4 virus vaccine
EP1159968A1 (en) * 2000-05-30 2001-12-05 Mahidol University Attenuated strains of Dengue virus and their use in a vaccine composition
WO2003101397A2 (en) * 2002-05-31 2003-12-11 Acambis, Inc. Tetravalent dengue vaccines

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040933A1 (en) 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
IL131600A0 (en) 1997-02-28 2001-01-28 Ora Vax Inc Chimeric flavivirus vaccines
EP1080370A4 (en) 1998-05-29 2003-07-30 Epimmune Inc Identification of broadly reactive dr restricted epitopes
JP2002540170A (en) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ Attenuated dengue type 2 virus vaccine
CN1191092C (en) * 1999-03-26 2005-03-02 沃尔特里德军事研究院 Multivaleng dengue virus vaccine
CA2365728A1 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-1 virus vaccine
CA2368790A1 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-3 virus vaccine
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
EP1263965B1 (en) 2000-02-16 2011-09-28 The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services Avirulent, immunogenic flavivirus chimeras
EP1159969A1 (en) 2000-05-30 2001-12-05 Aventis Pasteur Composition vaccinale
AT410634B (en) 2001-02-21 2003-06-25 Franz X Dr Heinz ATTENUATED LIFE VACCINE
EP2290108B1 (en) 2001-05-22 2014-07-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
JP2005518332A (en) 2001-05-23 2005-06-23 デンドレオン コーポレイション Conjugates activated by cell surface proteases and their therapeutic use
EP1401859B1 (en) 2001-06-01 2013-08-07 Sanofi Pasteur Biologics Co. Chimeric flavivirus vectors
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
BRPI0306905B8 (en) * 2002-01-15 2021-05-25 Acambis Inc method of producing an immunogenic/dengue composition comprising a flavivirus
CA2519953C (en) * 2003-03-24 2016-01-05 The Scripps Research Institute Dna vaccine against tumor growth and methods of use thereof
BRPI0613328A2 (en) * 2005-06-17 2011-01-04 Sanofi Pasteur live attenuated dengue-1 virus strain, immunogenic composition, vaccine composition, isolated nucleic acid, isolated polyprotein and polyprotein fragment
BRPI0614265A2 (en) * 2005-08-10 2011-03-22 Acambis Inc use of a yellow fever virus vaccine and a chimeric flavivirus vaccine and kit containing such vaccines
FR2903605A1 (en) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa IMMUNIZATION METHOD AGAINST THE FOUR SEROTYPES OF DENGUE
FR2909286B1 (en) * 2006-12-01 2012-06-08 Sanofi Pasteur IMMUNIZATION METHOD AGAINST THE 4 SEROTYPES OF DENGUE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057910A1 (en) * 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-4 virus vaccine
EP1159968A1 (en) * 2000-05-30 2001-12-05 Mahidol University Attenuated strains of Dengue virus and their use in a vaccine composition
WO2003101397A2 (en) * 2002-05-31 2003-12-11 Acambis, Inc. Tetravalent dengue vaccines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BHAMARAPRAVATI N ET AL: "Live attenuated tetravalent dengue vaccine", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 18, March 2000 (2000-03-01), pages 44 - 47, XP004203589, ISSN: 0264-410X *
HALSTEAD S B ET AL: "STUDIES ON THE IMMUNIZATION OF MONKEYS AGAINST DENGUE. II. PROTECTION FOLLOWING INOCULATION OF COMBINATIONS OF VIRUSES", AMERICAN JOURNAL OF TROPICAL MEDICINE & HYGIENE, LAWRENCE, KS, US, vol. 22, no. 3, May 1973 (1973-05-01), pages 375 - 381, XP009080918, ISSN: 0002-9637 *
ROTHMAN A L ET AL: "Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 19, no. 32, 14 September 2001 (2001-09-14), pages 4694 - 4699, XP004303162, ISSN: 0264-410X *
ZHOU ET AL: "Sculpting the immunological response to dengue fever by polytopic vaccination", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 24, no. 14, 24 March 2006 (2006-03-24), pages 2451 - 2459, XP005309251, ISSN: 0264-410X *

Also Published As

Publication number Publication date
ZA200901816B (en) 2010-06-30
IL224572A (en) 2014-06-30
IL197768A0 (en) 2011-08-01
US20080085288A1 (en) 2008-04-10
FR2906724B1 (en) 2009-03-20
CA2663885A1 (en) 2008-04-24
TW200826959A (en) 2008-07-01
US7718358B2 (en) 2010-05-18
TWI406673B (en) 2013-09-01
AR063057A1 (en) 2008-12-23
MX2009003417A (en) 2009-04-09
JP2010505801A (en) 2010-02-25
JP5269796B2 (en) 2013-08-21
WO2008047023A2 (en) 2008-04-24
AU2007311792B2 (en) 2013-05-02
AU2007311792A1 (en) 2008-04-24
BRPI0719849A2 (en) 2014-04-29
FR2906724A1 (en) 2008-04-11
EP2526964A1 (en) 2012-11-28
CN101553251B (en) 2013-05-22
CN101553251A (en) 2009-10-07
US20100270202A1 (en) 2010-10-28
EP2526965A1 (en) 2012-11-28
CN103285386A (en) 2013-09-11
KR20090064593A (en) 2009-06-19
TW201336508A (en) 2013-09-16
EP2077857B1 (en) 2013-11-20
EP2077857A2 (en) 2009-07-15

Similar Documents

Publication Publication Date Title
WO2008047023A3 (en) Immunisation method against the 4 dengue serotypes
MY169275A (en) Method of immunization against the four serotypes of dengue
MY180698A (en) Immunization protocol against the 4 dengue serotypes
NO20072733L (en) Dosage forms
WO2007131168A3 (en) Inhibitors of secretion of hepatitis b virus antigens for treatment of a chronic hepatitis virus
NO20055000L (en) Method of preventing hot bloat using gab analogues prodrug
WO2007047146A3 (en) Inhibitors of viral replication
WO2006008639A8 (en) Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
JP2010505801A5 (en)
WO2008005511A8 (en) Novel inhibitors of hepatitis c virus replication
WO2007111940A3 (en) Regimens for immunisation with meningococcal conjugates
WO2008137779A3 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
TN2009000481A1 (en) Novel peptide inhibitors of hepatitis c virus replication
MD20140058A2 (en) Compositions and methods for treating hepatitis C virus
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
WO2008156550A3 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
NO20080827L (en) Solid dosage formulations of narcotic drugs that have improved buccal adsorption
WO2010062581A3 (en) A botanical composition for enhanced skin repair and uses thereof
JP2007508326A5 (en)
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
WO2007027477A3 (en) Treating vulvodynia using prodrugs of gaba analogs
WO2008024843A3 (en) Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein
WO2004012655A3 (en) Anti-microbial compositions and methods of using same
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
BRPI0415953B8 (en) controlled release dosage formulation and set of controlled release dosage forms

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780044429.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07858487

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007311792

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2663885

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/003417

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1806/CHENP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2009530916

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007311792

Country of ref document: AU

Date of ref document: 20071002

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007858487

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020097008657

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0719849

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090331